MEDTHERAPY Trademark

Trademark Overview

On Wednesday, July 5, 2023, a trademark application was filed for MEDTHERAPY with the United States Patent and Trademark Office. The USPTO has given the MEDTHERAPY trademark a serial number of 98071706. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Friday, April 18, 2025. This trademark is owned by Medtherapy Biotechnology Inc.. The MEDTHERAPY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research services; research and development of cancer pharmaceuticals
medtherapy

General Information

Serial Number98071706
Word MarkMEDTHERAPY
Filing DateWednesday, July 5, 2023
Status760 - EX PARTE APPEAL PENDING
Status DateFriday, April 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Pseudo MarkMEDICAL THERAPY
Goods and ServicesPharmaceutical research services; research and development of cancer pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 4, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMedtherapy Biotechnology Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressQuincy, MA 02169

Trademark Events

Event DateEvent Description
Saturday, July 8, 2023NEW APPLICATION ENTERED
Friday, August 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 18, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sunday, March 17, 2024ASSIGNED TO EXAMINER
Monday, March 25, 2024NON-FINAL ACTION WRITTEN
Monday, March 25, 2024NON-FINAL ACTION E-MAILED
Monday, March 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 18, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Saturday, September 7, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 6, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 25, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, November 25, 2024FINAL REFUSAL WRITTEN
Friday, March 7, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, November 25, 2024FINAL REFUSAL E-MAILED
Tuesday, February 4, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, February 4, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, March 7, 2025EXPARTE APPEAL RECEIVED AT TTAB
Friday, March 7, 2025JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, March 7, 2025EX PARTE APPEAL-INSTITUTED
Tuesday, March 25, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 25, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 25, 2025ASSIGNED TO LIE
Friday, April 11, 2025ACTION CONTINUING FINAL - COMPLETED
Friday, April 11, 2025ACTION DENYING REQ FOR RECON E-MAILED
Friday, April 11, 2025NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED

Related Keywords

medtherapy research pharmaceuticals cancer services pharmaceutical development